SEQUENCE LISTING < 110 > Biotest AG ImmunoGen , Inc . < 120 > IMMUNOCONJUGATES TARGETING CD 138 AND USES THEREOF < 130 > 319935 . WO / JND / CJS < 150 > 61 / 016 , 620 < 151 > 2007 - 12 - 26 < 150 > 61 / 087 , 466 < 151 > 2008 - 08 - 08 < 150 > 61 / 087 , 590 < 151 > 2008 - 08 - 08 < 160 > 13 < 170 > PatentIn version 3 . 5 < 210 > 1 < 211 > 448 < 212 > PRT < 213 > Artificial Sequence < 220 > < 223 > Amino Acid sequence ( predicted ) of heavy chain of chimeric human / mouse antibody < 220 > < 221 > SITE < 222 > ( 31 ) . .( 35 ) < 223 > CDR 1 < 220 > < 221 > SITE < 222 > ( 51 ) . .( 68 ) < 223 > CDR 2 < 220 > < 221 > SITE < 222 > ( 99 ) . .( 111 ) < 223 > CDR 3 < 220 > < 221 > SITE < 222 > ( 123 ) . .( 448 ) < 223 > region IgG 4 < 400 > 1 Gln Val Gln Leu Gln Gln Ser Gly Ser Glu Leu Met Met Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Ser Asn Tyr 20 25 30 Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Leu Pro Gly Thr Gly Arg Thr Ile Tyr Asn Glu Lys Phe 50 55 60 Lys Gly Lys Ala Thr Phe Thr Ala Asp Ile Ser Ser Asn Thr Val Gln 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Asp Tyr Tyr Gly Asn Phe Tyr Tyr Ala Met Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr 210 215 220 Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp 260 265 270 Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 < 210 > 2 < 211 > 214 < 212 > PRT < 213 > Artificial Sequence < 220 > < 223 > Amino Acid sequence ( predicted ) of light chain of chimeric human / mouse antibody < 220 > < 221 > SITE < 222 > ( 24 ) . .( 34 ) < 223 > CDR 1 < 220 > < 221 > SITE < 222 > ( 50 ) . .( 56 ) < 223 > CDR 2 < 220 > < 221 > SITE < 222 > ( 89 ) . .( 97 ) < 223 > CDR 3 < 220 > < 221 > SITE < 222 > ( 108 ) . .( 214 ) < 223 > region IgG 4 < 400 > 2 Asp Ile Gln Met Thr Gln Ser Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Asn Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Glu Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 65 70 75 80 Glu Asp Ile Gly Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Arg 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 < 210 > 3 < 211 > 31 < 212 > DNA < 213 > Artificial Sequence < 220 > < 223 > IgH primer MHV 7 < 400 > 3 atgggcatca agatggagtc acagacccag g 31 < 210 > 4 < 211 > 21 < 212 > DNA < 213 > Artificial Sequence < 220 > < 223 > IgG 1 constant region primer MHCG 1 < 400 > 4 cagtggatag acagatgggg g 21 < 210 > 5 < 211 > 30 < 212 > DNA < 213 > Artificial Sequence < 220 > < 223 > Ig kappa primer MKV 2 < 400 > 5 atggagacag acacactcct gctatgggtg 30 < 210 > 6 < 211 > 33 < 212 > DNA < 213 > Artificial Sequence < 220 > < 223 > Ig kappa primer MKV 4 < 400 > 6 atgagggccc ctgctcagtt ttttggcttc ttg 33 < 210 > 7 < 211 > 25 < 212 > DNA < 213 > Artificial Sequence < 220 > < 223 > Ig kappa primer MKV 9 < 400 > 7 atggtatcca cacctcagtt ccttg 25 < 210 > 8 < 211 > 20 < 212 > DNA < 213 > Artificial Sequence < 220 > < 223 > primer MKC < 400 > 8 actggatggt gggaagatgg 20 < 210 > 9 < 211 > 50 < 212 > DNA < 213 > Artificial Sequence < 220 > < 223 > forward ( For ) primer < 400 > 9 agagaagctt gccgccacca tgattgcctc tgctcagttc cttggtctcc 50 < 210 > 10 < 211 > 35 < 212 > DNA < 213 > Artificial Sequence < 220 > < 223 > oligonucleotide primer BT 03 < 400 > 10 caacagtata gtaagctccc tcggacgttc ggtgg 35 < 210 > 11 < 211 > 35 < 212 > DNA < 213 > Artificial Sequence < 220 > < 223 > oligonucleotide primer BT 04 < 400 > 11 ccaccgaacg tccgagggag cttactatac tgttg 35 < 210 > 12 < 211 > 41 < 212 > DNA < 213 > Artificial Sequence < 220 > < 223 > primer g 2258 < 400 > 12 cgcgggatcc actcacgttt gatttccagc ttggtgcctc c 41 < 210 > 13 < 211 > 45 < 212 > DNA < 213 > Artificial Sequence < 220 > < 223 > Primer g 22949 < 400 > 13 cgatgggccc ttggtggagg ctgaggagac ggtgactgag gttcc 45